Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 501–600 of 1,001
Jirapinyo, P., Jaroenlapnopparat, A., & Thompson, C. C. (2024) · Endoscopy International Open · doi:10.1055/a-2463-9784 · Cited by 17
Dong, C., Zhou, B., Zhao, B., Lin, K., Tian, Y., Zhang, R., Xie, D., Wu, S., & Yang, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.006 · Cited by 20
DNA Methylation in Obesity and Associated Diseases
Crujeiras, A. B., & Díaz‐Lagares, Á. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801899-6.00016-4 · Cited by 19
Treatment satisfaction with different weight loss methods among respondents with obesity
Gupta, S., & Wang, Z. (2016) · Clinical Obesity · doi:10.1111/cob.12140 · Cited by 19
“A number of weight loss (WL) techniques have been recommended by the National Heart, Lung and Blood Institute (NHLBI) (12) and Endocrine Society (13) for overweight and obese adults in the US, including dietary restrictions, physical activity, behaviour therapy, pharmacotherapy and surgery.”
BackgroundResultInfluentialObesity and the diagnostic accuracy for primary aldosteronism
Tirosh, A., Hannah‐Shmouni, F., Lyssikatos, C., Belyavskaya, E., Zilbermint, M. F., Abraham, S. B., Lodish, M. B., & Stratakis, C. A. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13041 · Cited by 17
Surgical and Nonsurgical Weight Loss for Patients with Obstructive Sleep Apnea
Saunders, K. H., Igel, L. I., & Tchang, B. G. (2020) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2020.02.003 · Cited by 16
Qin, N., Song, G., Ren, X., Zhang, L., Gao, J., Xia, X., & Zhu, B. (2020) · Food & Function · doi:10.1039/d0fo00911c · Cited by 19
Sinisgalli, C., Vezza, T., Diez‐Echave, P., Ostuni, A., Faraone, I., Hidalgo‐Garcia, L., Russo, D., Armentano, M. F., Garrido‐Mesa, J., Rodríguez‐Cabezas, M. E., et al. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000812 · Cited by 18
Pharmacologic Weight Management in the Era of Adolescent Obesity
Raman, V. S., Gupta, A., Ashraf, A. P., Breidbart, E., Gourgari, E., Kamboj, M. K., Kohn, B., Krishnan, S., Lahoti, A., Matlock, K. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac418 · Cited by 15
Chakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155531 · Cited by 16
Regulation of food intake and the development of anti-obesity drugs
Chen, Y. (2016) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2016.01014 · Cited by 21
Extensive Phenotyping for Potential Weight-Inducing Factors in an Outpatient Population with Obesity
Savas, M., Wester, V. L., Visser, J. A., Kleinendorst, L., van der Zwaag, B., van Haelst, M. M., van den Akker, E. L. T., & van Rossum, E. F. C. (2019) · Obesity Facts · doi:10.1159/000499978 · Cited by 18
Evaluation of multidisciplinary weight loss shared medical appointments
Yager, S., Parker, M., Luxenburg, J., & Varghai, N. H. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.07.014 · Cited by 14
Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020) · International Journal of Endocrinology · doi:10.1155/2020/9649838 · Cited by 14
“In these conditions, hypogonadism is related to a progressive worsening of the disease, despite an adequate therapy (for instance, the failure of diet in obese men) [5], contributing to the evolution by an unfavourable vicious circle.”
BackgroundTronieri, J. S., Alfaris, N., Chao, A. M., Pearl, R. L., Alamuddin, N., Bakizada, Z. M., Berkowitz, R. I., & Wadden, T. A. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.06.004 · Cited by 15
Weight self-stigma and engagement among obese students in a physical education class
Zhang, B. G., & Qian, X. F. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1035827 · Cited by 19
“Furthermore, moderate physical activity is one of the best tools to alleviate the complications associated with obesity (Apovian et al., 2015).”
BackgroundLee, K., Akinola, A., & Abraham, S. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.29 · Cited by 14
“24,25 Current psychiatric guidelines are in need of updating, as they have yet to incorporate recent developments – such as new candidate medications (e.g. olanzapine/ samidorphan) 31 or recently published human trials 30 – and continue to include medications withdrawn from the market (e.g.…”
BackgroundForte, P. M., Encarnação, S., Monteiro, A. M., Teixeira, J. E., Hattabi, S., Sortwell, A., Branquinho, L., Amaro, B., Sampaio, T., Flores, P., et al. (2023) · Behavioral Sciences · doi:10.3390/bs13070522 · Cited by 19
“The BMI percentiles and categories are explained by several factors such as genetics [40], environment [41], a lifestyle based on diet [42], physical activity [43], comorbidities associated with other diseases [44], medication [45], sleep quality [46], and health problems related to metabolic syndrome [47].”
BackgroundGalindo, R. J., Uppal, T. S., McCoy, R. G., Umpierrez, G. E., & Ali, M. K. (2023) · Obesity · doi:10.1002/oby.23869 · Cited by 14
“Although our findings demonstrated a trend towards guideline-recommended management of overweight/obesity in adults with diabetes [ 5, 10, 11] ( 4 to 20 times more likely to use diabetes-specific WI medications (48% – 64”
BackgroundMethodResultInfluentialAntiobesity pharmacotherapy to facilitate living kidney donation
Orandi, B. J., Lofton, H. F., Montgomery, R. A., & Segev, D. L. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.12.003 · Cited by 16
Weight Loss Interventions for Adults With Obesity-Related Asthma
Foer, D., Forno, E., Holguín, F., & Cahill, K. N. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.041 · Cited by 19
Bagheri, M., Tanrıverdi, K., Iafrati, M. D., Mosley, J. D., Freedman, J. E., & Ferguson, J. F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155955 · Cited by 17
Christensen, S. M., & Nelson, C. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100175 · Cited by 21
“In general, more frequent contact leads to better outcomes [54].”
Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trials
Weissman, N. J., Smith, S. R., Fain, R., Hall, N., & Shanahan, W. R. (2016) · Obesity · doi:10.1002/oby.21695 · Cited by 14
“The Endocrine Society Clinical Practice Guideline for the Pharmacological Management of Obesity suggests the use of lorcaserin for weight management in patients with established cardiovascular disease (33), since, unlike some other antiobesity agents (29,34), it is not a sympathomimetic agent (33).”
BackgroundLuo, S., Lenon, G. B., Gill, H. S., Yuen, H., Yang, A. W. H., Hung, A., & Nguyen, L. T. (2018) · Current Drug Targets · doi:10.2174/1389450119666180830125958 · Cited by 14
Sato, M., Goto, T., Inoue, E., Miyaguchi, Y., & Toyoda, A. (2019) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.65.19 · Cited by 14
OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention
Peterson, S. J., Choudhary, A., Kalsi, A., Zhao, S., Alex, R., & Abraham, N. G. (2020) · Diagnostics · doi:10.3390/diagnostics10110976 · Cited by 15
Endoscopic Approaches to Obesity Management
Dolan, R. D., & Schulman, A. R. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-125832 · Cited by 18
Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
Williams, D. M., Staff, M., Bain, S. C., & Min, T. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.43 · Cited by 19
“However, orlistat commonly causes intolerable gastrointestinal side effects, such as steatorrhea and malabsorption of fat-soluble vitamins, which limit its use.(14) The estimated cost per quality-adjusted life year (QALY) is up to £45,881, limiting its use in the UK following the recommendation by the National Institu…”
BackgroundSchwartz, S. S., & Herman, M. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1043182 · Cited by 15
“These therapies were recently reviewed by the Endocrine Society [125].”
BackgroundPi-Sunyer, X., Shanahan, W. R., Fain, R., Ma, T., & Garvey, W. T. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1208618 · Cited by 15
Nio, Y., Hotta, N., Maruyama, M., Hamagami, K., Nagi, T., Funata, M., Sakamoto, J., Nakakariya, M., Amano, N., Okawa, T., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1825 · Cited by 19
Duque, I. D. E. (2017) · Universitas Médica · doi:10.11144/javeriana.umed58-2.obes · Cited by 24
Muzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 17
▼Naltrexone/bupropion for obesity
(2017) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2017.11.0550 · Cited by 20
“The current approach to treating obesity is via weight management programmes that support people to modify their diet, increase physical activity and change behaviour.(2,5,6) Weight loss of 5–10% over a period of 6 months is required to reduce the long-term risks associated with obesity.”
BackgroundRole of Bupropion Plus Naltrexone for the Management of Obesity
Booth, K., & Clements, J. N. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122515624220 · Cited by 13
“It has a similar indication as other approved medications, such as lorcaserin and phentermine plus topiramate, and all are supported by the guidelines for pharmacologic interventions in obesity management.(8-12) The article reviews the clinical evidence of bupropion plus naltrexone for obesity management.”
BackgroundSetmelanotide for the Treatment of Acquired Hypothalamic Obesity
Miller, J. L., van Santen, H. M., Phillips, S. A., Hamilton, J., Aberle, J., Sathyapalan, T., Mohamed, Z., McCormack, S. E., Shoemaker, A. H., Kelsey, M. M., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512275 · Cited by 17
Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices
daSilva‐deAbreu, A., Rodgers, J. E., Seltz, J., Mandras, S. A., Lavie, C. J., Loro-Ferrer, J. F., Ventura, H. O., Schauer, P. R., & Vest, A. R. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.006 · Cited by 14
Assessing the state of obesity care: Quality, access, guidelines, and standards
Kaplan, L. M., Apovian, C. M., Ard, J. D., Allison, D. B., Aronne, L. J., Batterham, R. L., Busetto, L., Dicker, D., Horn, D. B., Kelly, A. S., et al. (2024) · Obesity Science & Practice · doi:10.1002/osp4.765 · Cited by 20
“57 Until 2013, orlistat was the only obesity medication approved by regulatory agencies worldwide, along with phentermine (for short ‐ term treat-ment) in the U.S. Newer obesity medications have subsequently been approved for long ‐ term treatment, making effective and safe obesity medications…”
BackgroundSelf-citationTrinh, H., Donovan, A., & McAdam‐Marx, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16343 · Cited by 18
Use of Home Enteral Nutrition in Malnourished Post‐Bariatric Surgery Patients
Velapati, S. R., Schroeder, S. E., Schroeder, D. R., Buttar, N. S., Elfadil, O. M., Hurt, R. T., & Mundi, M. S. (2020) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1973 · Cited by 17
Yu, Y., He, X., Zhang, J., Tang, C., & Rong, P. (2021) · Science Progress · doi:10.1177/00368504211009669 · Cited by 13
“Currently, there are multiple pharmacological and surgical management options for obesity.(5,6) In recent years, neuromodulation of the vagal nerve for the treatment of obesity has attracted increasing attention.”
BackgroundTian, D., Chen, W., Xu, Q., Li, X., & Lv, Q. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07085-3 · Cited by 17
El‐Zawawy, H. T., El-Aghoury, A. A., Katri, K. M., Elsharkawy, E. M., & Gad, S. M. S. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00997-x · Cited by 13
Impact of a pharmacist-run weight loss medication management service
Haverkamp, K., Newberry, P., & Baker, J. W. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.11.022 · Cited by 17
Valença, H. D. M., Silva, C. P. E., de Brito‐Gitirana, L., Valença, S. S., & Lanzetti, M. (2022) · Phytotherapy Research · doi:10.1002/ptr.7377 · Cited by 15
“cological interventions are needed when individuals do not reach the desired levels of weight loss or improvement in comorbidities (Apovian et al., 2015).”
BackgroundZizmare, L., Boyle, C. N., Buss, S., Louis, S., Kuebler, L., Mulay, K., Krüger, R., Steinhauer, L., Mack, I., Gomez, M. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031126 · Cited by 15
“Beyond classical dietary and drug treatment [17,18], currently available approaches to treat morbid obesity and type 2 diabetes include bariatric surgery [19].”
BackgroundAnti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 21
Wujie, Y. E., Xing, J., Zekai, Y. U., Xingang, H. U., & Yan, Z. (2022) · PubMed · doi:10.19852/j.cnki.jtcm.2022.06.002 · Cited by 19
Advances in endobariatrics: past, present, and future
Shenoy, A., & Schulman, A. R. (2022) · Gastroenterology report · doi:10.1093/gastro/goad043 · Cited by 15
A case report of malignant obesity hypoventilation syndrome: A weighty problem in our ICUs
Tatusov, M., Joseph, J. J., & Cuneo, B. M. (2016) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2016.11.005 · Cited by 16
Chang, J. J., Bena, J., Kannan, S., Kim, J., Burguera, B., & Kashyap, S. R. (2017) · Endocrine Practice · doi:10.4158/ep161383.or · Cited by 13
Bariatric Arterial Embolization for Obesity: A Review of Early Clinical Evidence
Zhong, B., Abiola, G. O., & Weiss, C. R. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-1996-y · Cited by 12
“reduce appetite, enhance satiety, or decrease the absorption of fat [20, 21].”
A review and critique of published real-world weight management program studies
Primack, C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1498280 · Cited by 15
“With regard to weight loss program components, this review revealed a number of lapses from clinical guidelines for the treatment of obesity promulgated by The Obesity Society /Endocrine Society [122], AACE/ACE [4] and the Obesity Medicine Association [23] which encourage reduced-calorie diets in concert with physical…”
BackgroundSimonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 13
Pharmacotherapy of obesity in complex diseases
Pulipati, V. P., & Pannain, S. (2021) · Clinical Obesity · doi:10.1111/cob.12497 · Cited by 15
“Table 5 lists the impact of currently approved anti-DM, anti-HTN, anti-psychotic, antidepressant medications, and mood stabilizers on weight.(40,41) 1.”
BackgroundVangoitsenhoven, R., van der Ende, M., Corbeels, K., da Cunha, J. P. M. C. M., Lannoo, M., Bédossa, P., der Merwe, V., Mertens, A. C., Gesquiere, I., Meulemans, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200779 · Cited by 14
Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors
Green, L., & Taddei-Allen, P. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.564 · Cited by 13
Megawati, G., Indraswari, N., Johansyah, A. A., Kezia, C., Herawati, D. M. D., Gurnida, D. A., & Musfiroh, I. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186734 · Cited by 15
Yadav, R., Nigam, A., Mishra, R., Gupta, S. K., Chaudhary, A. A., Khan, S.-U.-D., Almuqri, E. A., Ahmed, Z. H., Rustagi, S., Singh, D. P., et al. (2024) · Medical Sciences · doi:10.3390/medsci12040055 · Cited by 17
Davies, M. L., Pham, D. Q., & Drab, S. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1792 · Cited by 12
“The addition of a GLP-1 RA was added as a recommendation in overweight and obese patients who use insulin in the Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline.30 It is proposed that most weight gain associated with insulin occurs within the first 1–2 years after initiation of…”
BackgroundMethodInfluentialPharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
“Orlistat provides a reasonable overall benefit to risk ratio as a weight-loss drug [43,63,74,75]; however, the associated gastrointestinal side effects including flatulence and oily stools leads to treatment discontinuation in many people (Table 1).”
BackgroundExpert consensus on management of metabolic disease in Chinese liver transplant recipients
Shen, T. H., Zhuang, L., Sun, X.-D., Qi, X., Wang, Z., Li, R.-D., Chang, W., Yang, J., Yang, Y., Zheng, S.-S., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i27.3851 · Cited by 12
Oral Superabsorbent Hydrogel (Plenity) for Weight Management
Pass, A., Bialonczyk, D., Chiquette, E., & Goldman, J. D. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020983046 · Cited by 13
Bisphenol F Exposure in Adolescent Heterogeneous Stock Rats Affects Growth and Adiposity
Wagner, V. A., Clark, K. C., CARRILLO-SÁENZ, L., Holl, K., Velez-Bermudez, M. E., Simonsen, D., Grobe, J. L., Wang, K., Thurman, A. L., Woods, L. C. S., et al. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab035 · Cited by 13
Zhang, W., Chen, X., Wang, C., Gao, L., Chen, W., Yang, W., & Collaborative, O. B. O. C. O. A. M. S. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05755-6 · Cited by 13
“Patients who have a history of being unable to successfully lose and maintain weight and who meet label indications are candidates for weight loss medications [26].”
BackgroundTirzepatide: A New Generation Therapeutic for Diabetes Type 2
Al‐Horani, R. A., & Chedid, M. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666221004151212 · Cited by 15
Cruciani, S., Delitala, A., Cossu, M. L., Ventura, C., & Maioli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032310 · Cited by 21
Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity
Saunders, K. H., Kumar, R. B., Igel, L. I., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0589-y · Cited by 13
Self-citationObesity and Management of Weight Loss
Yeh, J. S.-J., Kushner, R. F., & Schiff, G. D. (2016) · New England Journal of Medicine · doi:10.1056/nejmclde1515935 · Cited by 14
Morales-Estrella, J. L., Ciftci, F. D., Trick, W. E., & Hinami, K. (2017) · Quality of Life Research · doi:10.1007/s11136-017-1549-x · Cited by 12
Food Insecurity: It Is More Common Than You Think, Recognizing It Can Improve the Care You Give
Patil, S. P., Craven, K., & Kolasa, K. M. (2017) · Nutrition Today · doi:10.1097/nt.0000000000000232 · Cited by 16
Addressing Obesity in Clinical Gynecology Practice
Kahan, S. I., & Winston, G. J. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000334 · Cited by 14
Schneider, M. K., Xue, B., & Shi, H. (2018) · Physiological Reports · doi:10.14814/phy2.13645 · Cited by 15
Nuijten, M. J. C., Marczewska, A. M., Torres, K. A., Rasouli, B. S., & Perugini, M. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1468334 · Cited by 13
How to Incorporate Bariatric Training Into Your Fellowship Program
Jirapinyo, P., & Thompson, C. C. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.030 · Cited by 12
An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity
Tchang, B. G., Abel, B., Zecca, C., Saunders, K. H., & Shukla, A. P. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1685496 · Cited by 12
“Treatment of obesity reduces the risk of comorbidities and overall mortality [4].”
BackgroundCurrent treatment landscape for obesity in Singapore
Lee, P. C., Lim, C. H., Asokkumar, R., & Chua, M. W. J. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-216 · Cited by 16
“4% is observed after 1 year of treatment with orlistat.[27,28] Gastrointestinal side effects, such as steatorrhoea, diarrhoea, oily spotting and faecal incontinence, are common and limit the use of orlistat.”
BackgroundAlshehri, A., AlFaris, N., Al Qahtani, A. M., Shams, M., & Yahia, M. (2023) · Clinical Obesity · doi:10.1111/cob.12594 · Cited by 11
“Anti-obesity medications are valuable tools for treatment of obesity.(26) Liraglutide 1.”
Weight gain in midlife women: Understanding drivers and underlying mechanisms
Grammatikopoulou, M. G., Nigdelis, M. P., & Goulis, D. G. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100406 · Cited by 22
Almazan, E., Schwartz, J. L., & Gudzune, K. A. (2023) · Clinical Obesity · doi:10.1111/cob.12609 · Cited by 14
“For weight-loss-promoting medications, we identified medications based on guidelines that included a variety of medications such as anticonvulsants, antidepressants and medications to treat Type 2 diabetes mellitus.(3) We used the same approach for weightgain-promoting medications, and identified medications within an…”
BackgroundMethodInfluentialAnti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
“87 Conversely, bariatric surgery therapies, most commonly either laparoscopy sleeve gastrectomy or laparoscopy Roux-en-Y gastric bypass, are a reasonable approach when the BMI is ≥ 35 kg/m 2 and can be considered for patients with metabolic disease (predominantly T2DM) with a BMI range of 30 to…”
He, M., Zhu, H., Dong, J., Lin, W.-Z., Li, B., Li, Y., & Ta, D. (2024) · Ultrasonics · doi:10.1016/j.ultras.2024.107488 · Cited by 14
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
“Patients with chronic malabsorption syndrome or cholestasis should also not use this medication (34).”
Sibutramine: efficacy and safety of prescribing in routine clinical practice
Romantsova, T. I. (2015) · Obesity and metabolism · doi:10.14341/omet2015318-24 · Cited by 14
Weight loss with or without intragastric balloon causes divergent effects on ghrelin cell expression
Mathus-Vliegen, E. M. H., Spångéus, A., Walter, S., & Ericson, A. (2020) · Obesity Science & Practice · doi:10.1002/osp4.478 · Cited by 12
The Bariatric-Metabolic Physician’s Role in Managing Clinically Severe Obesity
Matta-Coelho, C., Crane, J. D., Agius, R., & McGowan, B. M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00435-z · Cited by 14
Metabolic Consequences Of Weight Reduction
Farhana, A., & Rehman, A. U. (2021) · Cited by 20
Updates in Cardiovascular Disease Prevention, Diagnosis, and Treatment in Women
Jones, S., McNeil, M., & Koczo, A. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.10.008 · Cited by 14
El‐Khateeb, E., Elberri, E. I., Mosalam, E. M., Nooh, M. Z., Abdelsattar, S., Alghamdi, A. M., Alrubia, S., & Abdallah, M. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1153653 · Cited by 12
“However, metformin monotherapy is not recommended by the Endocrine Society Practice Guideline on Pharmacology for Obesity for obese patients who do not have metabolic complications such as diabetes due to its modest and inconsistent effects (Apovian et al., 2015).”
BackgroundClinical Management of Obesity in Women
Ahmad, N. N., Butsch, W. S., & Aidarous, S. (2016) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2016.01.007 · Cited by 13
Maintaining Weight Loss: an Ongoing Challenge
Sumithran, P., & Proietto, J. (2016) · Current Obesity Reports · doi:10.1007/s13679-016-0230-y · Cited by 12
“Food and Drug Administration for chronic weight management: lorcaserin (Belviq), the combination of phentermine and topiramate extended-release (Qsymia), the GLP-1 analogue liraglutide 3 mg (Saxenda) and combination naltrexone/bupropion (Contrave) [20].”
BackgroundTreating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Andrew, C. A., Saunders, K. H., Shukla, A. P., & Aronne, L. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561867 · Cited by 11
“metic, are considered medically appropriate options for patients with CVD according to these guidelines [15].”
BackgroundSelf-citationAchievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity
Dearborn, J. L., Viscoli, C. M., Young, L. H., Gorman, M., Furie, K. L., & Kernan, W. N. (2019) · Stroke · doi:10.1161/strokeaha.118.024008 · Cited by 11
Pendse, J., Vallejo, F., Parziale, A., Callanan, M., Tenner, C. T., & Alemán, J. O. (2021) · Obesity · doi:10.1002/oby.23075 · Cited by 13
“In addition to confirming weight loss rates similar to placebo-controlled studies for obesity pharmacotherapy (14), we also observed weight-negative effects of diabetes medications such as metformin (1) and empagliflozin (7) in the VA virtual cohort.”
BackgroundPerra, A., Preti, A., Lorenzo, V. D., Nardi, A. E., & Carta, M. G. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-020-01089-x · Cited by 14
How to Incorporate Bariatric Training Into Your Fellowship Program
Jirapinyo, P., & Thompson, C. C. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.034 · Cited by 11
Kan, H., Swindle, J. P., Bae, J., Dunn, J. P., Buysman, E. K., Gronroos, N. N., Bengtson, L., Chinthammit, C., Ford, J., & Ahmad, N. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100072 · Cited by 10
“27 kg/m 2 with an ORC in whom an LSI alone was unsuccessful [4,5,7,8].”
BackgroundPreconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment
Koceva, A., Janež, A., & Jensterle, M. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102038 · Cited by 17
Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance
Brufani, C., & Morviducci, L. (2025) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf011 · Cited by 11
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.